Rett Syndrome Research Trust

What Rett Syndrome Research Trust does

The Rett Syndrome Research Trust (RSRT) is a 501(c)(3) nonprofit patient advocacy organization founded in 2008 and headquartered in Trumbull, Connecticut. It is dedicated to curing Rett syndrome, a severe X-linked neurodevelopmental disorder caused by mutations in the MECP2 gene that produces loss of speech, hand use, and motor function in affected children. RSRT serves two primary constituencies: the global community of roughly 350,000 individuals affected by Rett syndrome and their families, and the academic and biotech researchers developing therapeutic candidates. Leadership comprises Founder & CEO Monica Coenraads and newly appointed Chief Medical Officer Genevieve Laforet, MD, PhD, with governance drawn substantially from parents of affected children.

RSRT operates as an MECP2 therapeutic incubator rather than a traditional grant-making foundation. Through its Roadmap to Cures 2.0 initiative (launched 2024, $40M goal) it funds and orchestrates a diversified portfolio of genetic medicine programs spanning gene therapy, base editing, prime editing, RNA editing, RNA trans-splicing, and MECP2 reactivation, alongside parallel delivery technologies including AAV, engineered exosomes (Evox Therapeutics), lipid nanoparticles (Jennifer Doudna's lab at UC Berkeley), and ribonucleoprotein complexes. Notable co-development partnerships include Beam Therapeutics (prime editing, theoretically reparable for up to 89% of Rett-causing mutations), Profluent Bio (AI-designed base editors), the AbuGoot Lab at Harvard (RNA trans-splicing, potentially mutation-agnostic), and Apertura Gene Therapy (novel brain-entry pathways). RSRT also operates the Rett Syndrome Global Registry, the VIBRANT biomarker study, and an annual Genetic Medicines Summit that in 2025 convened leadership from 45+ biopharma companies. Gene therapy programs now in clinical trials were originally started and incubated at RSRT.

RSRT is funded entirely through charitable giving: family-led crowdfunding via GoFundMe and Facebook Fundraisers, branded events such as Reverse Rett Philadelphia and Chicago and Miracle for Molly, direct donations, and matching-donor campaigns. The organization has cumulatively invested $92 million in Rett research since 2008, including $6.4 million awarded in 2025 alone. The number of biopharma companies with MECP2-targeted genetic medicine programs has grown from zero at the start of the 2017 Roadmap to six today. RSRT holds a Candid Gold Seal of Transparency and a 4-star Charity Navigator rating, and is registered as a U.S. 501(c)(3) (EIN: 26-0687439).

Name

Rett Syndrome Research Trust

Legal name

Rett Syndrome Research Trust

Website

https://reverserett.org

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

1–10 employees

Short description

The Rett Syndrome Research Trust is a 501(c)(3) nonprofit founded in 2008 that funds and incubates genetic medicine programs targeting MECP2 mutations. It serves the global Rett patient community and biotech researchers, with $92 million deployed across gene therapy, gene editing, and delivery technologies.

Ownership category

akta.pro rank

Product category

Medical Research Nonprofit

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Social Services (8300), Services-Health Services (8000)

akta.pro primary industry

Research Administration & Compliance (Sponsored Programs, IRB/REB) (EDADAKAH)

Keywords

• Rare disease research
• Genetic medicines funding
• Patient advocacy nonprofit
• Rett syndrome cures
• Biomedical research grants

Headquarters

HQ city

Trumbull

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Donations and Fundraising: RSRT generates revenue through donations from individuals, families affected by Rett syndrome, and supporters. Families actively fundraise through events, crowdfunding campaigns, and direct appeals.
2. Research Awards Funding: RSRT receives funding from various sources to award grants for Rett research, with cumulative investment reaching $92 million since 2008. 2025 awards totaled $6.4 million.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Rett Syndrome Research Trust (RSRT) is a patient advocacy nonprofit that funds and incubates genetic medicine research programs targeting MECP2 gene mutations, the root cause of Rett syndrome. It operates the Roadmap to Cures initiative, supports academic labs and biotech companies developing gene therapy, base editing, prime editing, RNA editing, RNA trans-splicing, and MECP2 reactivation approaches, and runs the Rett Syndrome Global Registry to support clinical trial readiness.

Product overview

Rett Syndrome Research Trust (RSRT) is a patient advocacy organization functioning as a strategic research funder and incubator, not a traditional product company. RSRT does not sell software products or services. Instead, it advances genetic medicine programs through its Roadmap to Cures initiative, which supports multiple therapeutic approaches including gene therapy, base editing, prime editing, RNA editing, RNA trans-splicing, and MECP2 reactivation. RSRT also operates the Rett Syndrome Global Registry for patient data collection and hosts the annual Genetic Medicines Summit to convene stakeholders. The organization's core activities are research funding, program incubation, and community engagement rather than product development or commercialization.

Differentiator

Problem solved

Functional benefit

Products and services

• Roadmap to Cures A $40 million strategic research initiative that funds and orchestrates genetic medicine programs targeting the root cause of Rett syndrome, encompassing cargo approaches (gene therapy, base editing, prime editing, RNA editing, RNA trans-splicing, MECP2 reactivation) and delivery technologies (viral and non-viral methods). Aimed at advancing three therapies to clinical trials by 2028.
• Rett Syndrome Global Registry A patient registry platform that collects and tracks data from individuals with Rett syndrome to support genetic medicine research, clinical trial readiness, and therapeutic development.
• VIBRANT Study A research program developing biomarkers and outcome measures to enable and de-risk clinical trials for Rett syndrome genetic medicines.
• Genetic Medicines Summit An annual three-day convening of leading scientists, clinicians, regulators, and biopharma company leadership to explore the genetic medicines landscape for Rett syndrome and inspire companies to add the disorder to their pipelines.

Quantifiable outcome

• Cumulative investment of $92 million in Rett research since 2008
• +4 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Evox TherapeuticscoreStrategic or Co-development Partner · 26 February 2026Collaboration to evaluate whether Evox Therapeutics' ExoEdit® exosome-based delivery platform can enable gene editing treatments for Rett syndrome. The partnership aims to address the key challenge of safely delivering gene editing therapies to the central nervous system, with successful findings potentially establishing a preclinical program targeting the majority of Rett syndrome patients.
• Profluent BiocoreStrategic or Co-development Partner · 19 November 2025Partnership using artificial intelligence to design personalized gene-editing therapies for Rett syndrome. Profluent will leverage its AI models to develop base editors that correct mutations in the MECP2 gene, starting with the T158M mutation. RSRT awarded Profluent $1 million in initial funding. This partnership aligns with RSRT's Roadmap to Cures program.
• Apertura Gene TherapycoreStrategic or Co-development Partner · 30 April 2025Partnership with Apertura Gene Therapy on new pathways into the brain for delivering genetic medicines. Part of Roadmap to Cures 2.0 initiative focused on delivery technologies.
• Gene Therapy Consortium 2.0coreStrategic or Co-development Partner · 13 December 2018World-class team comprised of James Wilson (UPENN), Adrian Bird (University of Edinburgh), and Stuart Cobb (University of Edinburgh) working on next generation gene therapy. The consortium has received almost $2.5 million in RSRT funding with goals including understanding MECP2 function and designing novel gene therapy cassettes.
• Jennifer Doudna Lab (UC Berkeley)coreStrategic or Co-development PartnerCollaboration on lipid nanoparticle delivery methods for genetic medicines targeting Rett syndrome. Part of RSRT's non-viral delivery strategy to address limitations of viral vectors such as inability to re-dose and cargo capacity constraints.
• AbuGoot Lab (Harvard Medical School)coreStrategic or Co-development PartnerRSRT awarded $858,000 to Omar Abuddayeh and Jonathan Gootenberg to advance RNA trans-splicing technology for Rett syndrome. This approach could potentially address all Rett mutations by replacing parts or the entire MECP2 gene with a single treatment that applies to all patients.
• Beam TherapeuticscoreStrategic or Co-development PartnerPartnership leveraging Beam Therapeutics' prime editing technology through a sublicense from Prime Medicine. Prime editing can potentially repair up to 89% of mutations causing Rett syndrome, including insertions, deletions, and all eight types of point mutations.
• ArmaGenminorStrategic or Co-development PartnerRSRT awarded $125,000 to ArmaGen for protein replacement therapy. ArmaGen's platform technology takes advantage of the body's natural system to non-invasively deliver drugs across the blood-brain barrier using transferrin receptors.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• National Organization for Rare Disorders (NORD): NORD is an umbrella advocacy organization representing the broader rare disease community across all conditions, including through research grants and policy advocacy. Comparable in its rare disease patient-advocacy nonprofit role but operates at a portfolio rather than single-disease level.
• EveryLife Foundation for Rare Diseases: EveryLife Foundation advocates for the rare disease community at the policy level and supports patient organizations in advancing research and access. Comparable as a rare disease advocacy nonprofit but operates as a convener and policy shop rather than a single-disease research incubator.

Direct peers

• Cystic Fibrosis Foundation: The Cystic Fibrosis Foundation is the gold-standard patient-led nonprofit that funded the science behind every CF modulator therapy. Like RSRT, it functions as a venture philanthropy incubator, taking research programs from academic labs to industry partnerships and clinical trials. Highly comparable as a rare disease research funder and accelerator.
• Foundation Fighting Blindness: Foundation Fighting Blindness funds inherited retinal disease research including gene therapy programs that have led to approved products (Luxturna). Comparable to RSRT as a rare disease research incubator that has successfully translated academic gene therapy science into clinical-stage assets.
• Tuberous Sclerosis Alliance: The Tuberous Sclerosis Alliance funds genetic research into TSC1/TSC2, supports clinical trials, and operates a patient registry. Comparable to RSRT in operating model, single-gene rare disease focus, and role as research funder convener.
• Parent Project Muscular Dystrophy (PPMD): PPMD is a patient-led nonprofit that funds Duchenne muscular dystrophy research, operates a patient registry, and runs an in-house Certified Duchenne Care Center network. Mirrors RSRT's combination of research funding, patient registry infrastructure, and advocacy for a single-gene neurodevelopmental disorder.
• Myelin Repair Foundation: The Myelin Repair Foundation operated as a venture philanthropy accelerator for multiple sclerosis research, applying a research roadmap model similar to RSRT's to identify and fund high-impact translational programs through academic and industry partnerships.
• Cure SMA: Cure SMA is a patient advocacy nonprofit that drove the development and approval of Spinraza, Zolgensma, and Evrysdi through research funding, clinical network building, and patient registry operation. Closely parallels RSRT's model of incubating genetic medicine programs and partnering with biopharma to advance them to clinical trials.
• Charcot-Marie-Tooth Association: CMTA funds research into CMT, a hereditary neuropathy, and has a strategy research roadmap analogous to RSRT's Roadmap to Cures, including grant programs and biotech partnerships. Comparable rare genetic neurological disease research funder with structured research investment plans.
• Friedreich's Ataxia Research Alliance (FARA): FARA is a patient-driven rare disease nonprofit that funds genetic medicine research for Friedreich's ataxia, partners with academic and industry researchers, and operates patient registries and biomarkers programs. Closely comparable structure and rare neuro-genetic disease focus to RSRT.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/watch?v=0vyOPjCUFPE
• Facebookfacebook.com/RettSyndromeResearchTrust
• Xx.com/RSRT

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rett Syndrome Research Trust